Kronos Bio Inc reports results for the quarter ended in June - Earnings Summary

Kronos Bio

09/08/2024 03:50

* Kronos Bio Inc  KRON.OQ  reported a quarterly adjusted
loss
of 27 cents​​ per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of -52 cents.  The mean expectation of four analysts for the
quarter was for a loss of 34 cents per share. Wall Street
expected results to range from -40 cents to -25 cents per share.
    * Revenue rose 44.2% to $2.69 million from a year ago;
analysts
expected $1.53 million. 
    * Kronos Bio Inc's reported EPS for the quarter was a loss
of 27
cents​.
    * The company reported a quarterly loss of $16.2 million.
    * Kronos Bio Inc shares had fallen by 10.5% this quarter and
lost 11.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 12.9%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Kronos Bio Inc is
$4.13 
This summary was machine generated from LSEG data August 9 at
02:50 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.34          -0.27          Beat
 Mar. 31 2024      -0.42          -0.29          Beat
 Dec. 31 2023      -0.52          -0.34          Beat
 Sep. 30 2023      -0.51          -0.54          Missed